Evidence map›Paper›PMID 27146293›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2016

Pleiotropic effects of statins: new therapeutic targets in drug design.

Onkar Bedi, Veena Dhawan, P L Sharma, Puneet Kumar

Abstract readHistorical ArticleReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 7 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 7 syntheses or guidelines pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Risk factors for venous thromboembolism in sickle cell disease.Research and practice in thrombosis and haemostasis · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Onkar BediDepartment of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
Veena DhawanDepartment of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
P L SharmaDepartment of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
Puneet KumarDepartment of Pharmacology, I.S.F College of Pharmacy, Moga, Punjab, 142001, India. punnubansal79@gmail.com.
Post Graduate Institute of Medical Education and Research · INIndo Soviet Friendship College of Pharmacy · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HMG Co-enzyme inhibitors and new lipid-modifying agents expand their new therapeutic target options in the field of medical profession. Statins have been described as the most effective class of drugs to reduce serum cholesterol levels. Since the discovery of the first statin nearly 30 years ago, these drugs have become the main therapeutic approach to lower cholesterol levels. The present scientific research demonstrates numerous non-lipid modifiable effects of statins termed as pleiotropic effects of statins, which could be beneficial for the treatment of various devastating disorders. The most important positive effects of statins are anti-inflammatory, anti-proliferative, antioxidant, immunomodulatory, neuroprotective, anti-diabetes, and antithrombotic, improving endothelial dysfunction and attenuating vascular remodeling besides many others which are discussed under the scope of this review. In particular, inhibition of Rho and its downstream target, Rho-associated coiled-coil-containing protein kinase (ROCK), and their agonistic action on peroxisome proliferator-activated receptors (PPARs) can be viewed as the principle mechanisms underlying the pleiotropic effects of statins. With gradually increasing knowledge of new therapeutic targets of statins, their use has also been advocated in chronic inflammatory disorders for example rheumatoid arthritis (RA) and in systemic lupus erythematosus (SLE). In the scope of review, we highlight statins and their pleiotropic effects with reference to their harmful and beneficial effects as a novel approach for their use in the treatment of devastating disorders. Graphical abstract Pleiotropic effect of statins.

Indexed as

Drug DesignAnimalsAnti-Inflammatory AgentsAntioxidantsCardiovascular AgentsDyslipidemiasHistory, 20th CenturyHistory, 21st CenturyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsImmunologic FactorsLipidsPeroxisome Proliferator-Activated ReceptorsProtein Kinase InhibitorsPurinergic P1 Receptor Agonistsrac1 GTP-Binding ProteinAnti-Inflammatory AgentsAntioxidantsCardiovascular AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsImmunologic FactorsLipidsPeroxisome Proliferator-Activated ReceptorsProtein Kinase InhibitorsPurinergic P1 Receptor Agonistsrac1 GTP-Binding Proteinrho-Associated KinasesAnti-inflammatoryAtheroscleroticPleiotropic effectsRheumatoid arthritisStatins

Identifiers

PMID27146293
OpenAlexW2346664883

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.